Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) for Prostate Cancer
Overview Pluvicto is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who…